Policy implementation for inpatient management of U-500 insulin resulting in lower incidence of hypoglycemia

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages 521-

  Deal, Eli N ^a   Tobin, Garry S ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; TALSUPRAM;

CLINICAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HYPOGLYCEMIA; LETTER; MEDICAL DOCUMENTATION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DOSAGE FORMS; GUIDELINE ADHERENCE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INPATIENTS; INSULIN; PRACTICE GUIDELINES AS TOPIC;

EID: 79959637631     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Baumann G, Schwebke J. U-500 insulin for insulin resistance. Am J Med. 1985;79:A55.
2. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U-500 insulin: Why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23:265-268. (Pubitemid 46851466)
3. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67:1526-1535.